Tonix Pharmaceuticals Holding (TNXP) Price to Sales (2022 - 2026)

Tonix Pharmaceuticals Holding has reported Price to Sales for 5 years, with the latest figure at 15.82 in Q2 2026.

• On a quarterly basis, Price to Sales fell 88.36% year-over-year to 15.82 in Q2 2026; TTM through Jun 2026 was 7.36, a 73.34% decrease from a year earlier, with the FY2025 full-year figure at 10.14, up 321.35% from the prior year.
• Price to Sales was 15.82 for Q2 2026 at Tonix Pharmaceuticals Holding, down from 28.4 in the prior quarter.
• The five-year high for Price to Sales was 135.89 in Q2 2025, with the low at 1.3 in Q2 2024.
• Average Price to Sales over 5 years is 24.82, with a median of 7.47 recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Price to Sales soared 10392.93% in 2025, then sank 88.36% in 2026.
• Over 5 years, Price to Sales stood at 6.12 in 2022, then tumbled by 70.5% to 1.8 in 2023, then surged by 421.77% to 9.41 in 2024, then jumped by 162.09% to 24.67 in 2025, then sank by 35.86% to 15.82 in 2026.
• The last three Price to Sales figures came in at 15.82 (Q2 2026), 28.4 (Q1 2026), and 24.67 (Q4 2025), per Business Quant data.